• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

SMND-309 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755540

SMND-309 is a metabolite of salvianolic acid B. It also shows neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats. More details

DISCONTINUED
Click here to view our similar product(s) OR click here to contact our technical support team for suitable replacement.
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Product Name
SMND-309, Inhibitor
Full Product Name
SMND-309
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
358.3
Solubility
DMSO: 3.7mg/mL (10.33mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C18H14O8
SMILES
OC1=C(C(/C=C/C(O)=O)=CC=C1O)/C(C(O)=O)=C\C2=CC(O)=C(C=C2)O
CAS Number
1065559-56-9
Target & IC50
Others
In Vitro
SMND-309 treatment,decreases the liver damage and the liver fibrosis grade. SMND-309 also reduces the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment,powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver. SMND-309 (2.5-10mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment,ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue [1].

Structure of SMND-309, inhibitor

SMND-309 Inhibitor – Cat# MBS5755540

Product References and Citations for SMND-309, inhibitor

Hou J, Tian J, Jiang W, Gao Y, Fu F. Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis. Eur J Pharmacol. 2011 Jan 10;650(1):390-5.
Hou J, Tian J, Jiang W, Gao Y, Fu F. Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis. Eur J Pharmacol. 2011 Jan 10;650(1):390-5.
Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J. Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats. Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23.
Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J. Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats. Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23.

Other Notes

Small volumes of SMND-309, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for SMND-309 purchase

MBS5755540 is an inhibitor targeting SMND-309.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000